Business
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022Study initiated to assess impact of Nociscan on the cost of care for chronic low
About this update from Aclarion, Inc.
[{"type":"text","content":"Initial findings from the EVAL study are expected to be released in Q4 2022Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patientsPromising initial clinical evaluations with 87% of patients treated at discs identified as painful by Nociscan continuing to show significant clinical improvements at a two-year follow-upBROOMFIELD, CO / ACCESSWIRE / July 20, 2022 / Aclarion, Inc., (\"Aclarion\" or the \"Company\") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the launch of the Economic Value Analysis of Low back pain (EVAL) study; a rigorous healthcare economic study to assess the impact of the Nociscan solution on the cost of care for patients suffering from chronic low back pain (CLBP). The University of California at San Francisco and the Center for Disruptive Musculoskeletal Innovations (CDMI), which is funded by the National Science Foundation, is conducting the study using outcomes data from previously published clinical studies.Initial findings from the EVAL study are expected to be released in Q4 2022. The Company expects results of this study to provide strong economic support for the utilization of Nociscan in the assessment of CLBP and to use this data to accelerate coverage decisions from insurance companies and self-insured employers.\"Throughout my career, I have been interested in the nexus of health economics and spine care. Chronic low back pain has an important healthcare and social cost, and the EVAL study is valuable in guiding an evidence-based approach to appropriate care for patients with symptomatic disc degeneration,\" said Dr. Sigurd Berven, Professor of Orthopedic Surgery at University of California San Francisco School of Medicine. \"Aclarion's Nociscan solution is truly groundbreaking technology in the assessment of CLBP, and the EVAL study will provide a clear picture of the economic impact that Nociscan can have for the US healthcare system and for the appropriate management of patients with low back pain.\"Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud ...